Calculating Glucagon‐Like Pepide‐1 Receptor Agonist‐Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System | Synapse
April 22, 2026
Calculating Glucagon‐Like Pepide‐1 Receptor Agonist‐Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System
Key Points
This research aims to assess the risk of medullary thyroid cancer (MTC) linked to GLP-1 receptor agonists (GLP-1RAs).
Integrated data from the Surveillance, Epidemiology and End Results Cancer Registry and FDA Adverse Event Reporting System.
Compared risk of MTC between GLP-1RAs and other drug classes.
GLP-1RAs demonstrated a higher risk prediction for medullary thyroid cancer compared to other medications.
Findings suggest necessitating further prospective studies for validation.
Abstract
GLP-1RAs showed a higher RP for MTC compared to other drug classes, warranting prospective studies to investigate further.